Mankind Pharma is India’s youngest top-five drugmaker, built on a simple founding insight: patients in smaller towns could not afford full courses of medicine and often had to travel to bigger cities just to find the brands their doctors prescribed. Started in 1995 from Meerut by a founder who left a leading pharma job to solve that exact problem, the company adopted a bottom-up philosophy of “Affordability, Quality and Accessibility” - moving from villages to towns to cities, then across states, to build a pan-India presence. That same approach - go where the unmet need is, price for the mass market, and scale through a vast doctor-facing field force - now repeats across its expansion into chronic therapies, consumer health, and the complex super-specialty medicines it acquired with Bharat Serums and Vaccines.
Business segments
A single integrated pharmaceutical engine with four distinct go-to-market faces - a mass-market branded generics core, a consumer-health storefront, a newly acquired super-specialty platform, and an export tail - all fed by the same manufacturing and R&D backbone.
1. Domestic branded generics: the prescription engine that powers everything
A field force of over 18,500 representatives calls on five lakh doctors, generating the prescription volume that makes Mankind India’s #1 prescribed company for nine years running - and the cash flow that funds every other part of the business.
- Two sales forces for two doctor types - a mass-market team targets General Practitioners and Consulting Physicians with affordable acute and chronic brands, while a separate specialty division launched in 2020-21 calls on specialist MDs and Key Opinion Leaders with latest-generation chronic therapies priced at par with competitors, using a top-down approach in metro hospitals.
- Chronic therapies are the deliberate shift - the share of chronic prescriptions in the domestic mix has risen from 28% to roughly 40% over seven years, led by cardiac brands like Telmikind (now an INR 783 crore brand) and in-licensed products such as a heart-failure drug from Novartis and a cholesterol-lowering injectable.
- Brand depth creates staying power - 13 brands cross INR 200 crore in annual sales, 22 brand families exceed INR 100 crore, and three - Telmikind, Nurokind, and Manforce - each top INR 600 crore, giving the company pricing resilience and shelf-space pull with chemists.
- Manufacturing is mostly in-house - 32 factories produce over 44 billion units a year, with 75% of output made internally and over 95% of raw materials sourced locally, which keeps quality control tight and supply disruptions low.
2. Consumer healthcare: the over-the-counter storefront
Seven everyday health brands, four of them number one in their categories, sold through general trade, modern retail and e-commerce - a business carved into a separate subsidiary to sharpen its consumer-goods instincts.
- Rx-to-OTC pipeline - the company takes prescription molecules with established doctor trust and transitions them to over-the-counter brands, as it did with the multivitamin HealthOK and the anti-acne brand AcneStar, which now holds a 33% market share.
- Category leadership in intimate health - Manforce commands 28% of the condom market, Prega News holds 83% of pregnancy test kits, and Unwanted-72 has 68% of emergency contraception, creating a cluster of dominance in a high-repeat-purchase segment.
- Modern trade and e-commerce are the growth lever - these channels grew 57% year-on-year and now contribute 13% of the consumer business, up from 9% the year before, as the company shifts beyond chemist-shop dependence.
- Brand ambassadors do the heavy lifting - each major brand carries a recognisable face, from Amitabh Bachchan as corporate ambassador to Ranveer Singh for HealthOK and Anushka Sharma for Prega News, with campaigns spanning digital video, cinema, bus branding and on-ground sampling.
3. BSV super-specialty: the high-barrier biologics platform
Acquired for ₹13,768 crore in late 2024, Bharat Serums and Vaccines brings in-house recombinant technology, a lock on niche women’s-health and critical-care products, and a fertility portfolio sold globally - a business where competition is limited and scientific differentiation is the moat.
- Products competitors cannot easily copy - BSV makes the world’s only recombinant Anti-D immunoglobulin (100% market share) and India’s first anti-thymocyte immunoglobulin, built on proprietary platforms in recombinant technology, niche biologics and novel drug delivery.
- Women’s health across the lifecycle - the portfolio spans fertility drugs (Foligraf, HMG), pregnancy care (Ossopan, Lactare) and critical-care products, with 11 brand families each exceeding ₹25 crore in sales and the top 10 contributing 68% of BSV’s revenue.
- R&D is the engine, not an afterthought - BSV’s platform-based research model enables first-to-market launches, and a new manufacturing facility being built in Vadodara will add capacity and de-risk the existing Ambernath plant.
- Integration is underway - the women’s health prescription portfolio is being transferred to the parent company via a ₹797 crore slump sale, and a structural integration committee is evaluating how to fold BSV’s capabilities into Mankind’s wider ecosystem.
4. International business: the export tail
Exports to over 20 countries, anchored by 48 product launches in the US generics market and BSV’s specialty fertility brands in emerging markets - a 14% revenue slice that the company runs for incremental scale rather than as a primary growth bet.
- US generics via the ANDA route - the company has filed 67 Abbreviated New Drug Applications, of which 48 are approved, and has launched 48 products in total through its US subsidiary Lifestar Pharma.
- BSV adds a specialty export layer - BSV’s fertility and critical-care products already have traction in international markets, and a new Russian subsidiary was incorporated in 2025 as a wholly owned subsidiary of Mankind Pharma.
- Margin-neutral by design - export gross margins are lower than domestic, but operating expenses are leaner too, so the business delivers similar profitability without distracting management from the home market.
Group structure and partners
A listed parent with 36 subsidiaries, anchored by the BSV acquisition and a separately housed consumer business - plus a web of in-licensing deals with multinationals that fill therapy gaps without the cost of in-house discovery.
- Consumer healthcare sits in its own subsidiary - Mankind Consumer Products Private Limited was incorporated in 2024 and the OTC business was transferred via a slump sale, separating the consumer-goods operating model from the prescription-drug engine.
- API manufacturing was consolidated into the parent - three wholly owned API-making subsidiaries were amalgamated in 2025 to eliminate duplicate costs and integrate the supply chain directly into Mankind Pharma.
- In-licensing brings global molecules to Indian shelves - partnerships with Novartis (heart failure, cholesterol), AstraZeneca (asthma inhaler), Takeda (GERD), Biocon (insulin) and Innovent Biologics (cancer immunotherapy) give Mankind exclusive Indian rights to patented or complex therapies without bearing the upfront discovery risk.